Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-09-28
DOI
10.3389/fendo.2017.00254
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Induction of New Autoimmune Diseases After Alemtuzumab Therapy for Multiple Sclerosis
- (2017) Lawrence Steinman JAMA Neurology
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
- (2017) David Baker et al. JAMA Neurology
- Therapeutic strategies targeting B-cells in multiple sclerosis
- (2016) Ron Milo AUTOIMMUNITY REVIEWS
- Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis
- (2016) Mark Obermann et al. Multiple Sclerosis Journal
- Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis
- (2016) Mark Obermann et al. Multiple Sclerosis Journal
- Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any)
- (2016) L. Bartalena et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves’ Disease
- (2016) Hidefumi Inaba et al. Frontiers in Endocrinology
- Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management
- (2015) Moeber Mahzari et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Graves’ Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies
- (2015) S. Morshed et al. HORMONE AND METABOLIC RESEARCH
- Etiopathogenesis of Basedow’s disease
- (2015) P. Leporati et al. NUKLEARMEDIZIN-NUCLEAR MEDICINE
- Graves' disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently?
- (2014) Anthony P. Weetman CLINICAL ENDOCRINOLOGY
- Mode of action and clinical studies with alemtuzumab
- (2014) Joanne L. Jones et al. EXPERIMENTAL NEUROLOGY
- Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
- (2014) O. Tuohy et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Disease modifying therapies in multiple sclerosis: Could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
- (2014) Mario Rotondi et al. Multiple Sclerosis Journal
- Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study
- (2014) Giovanni Frisullo et al. Multiple Sclerosis Journal
- Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease
- (2014) Kristen M. Williams et al. PEDIATRIC BLOOD & CANCER
- Role of genetic and non-genetic factors in the etiology of Graves’ disease
- (2014) M. Marinò et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Autoimmune Thyroid Disease in the Use of Alemtuzumab for Multiple Sclerosis: A Review
- (2013) Algenes Aranha et al. Endocrine Practice
- Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis
- (2013) Gilbert H. Daniels et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Reprogramming the immune repertoire with alemtuzumab in MS
- (2013) Heinz Wiendl et al. Nature Reviews Neurology
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial
- (2012) A. J. Coles et al. NEUROLOGY
- Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis
- (2012) Sambasiva P. Rao et al. PLoS One
- The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study
- (2012) Ruth Ann Marrie et al. Multiple Sclerosis and Related Disorders
- The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
- (2011) Mario Rotondi et al. CURRENT PHARMACEUTICAL DESIGN
- Interferon-β but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: A clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs
- (2011) Mario Rotondi et al. JOURNAL OF NEUROIMMUNOLOGY
- T cells in multiple sclerosis and experimental autoimmune encephalomyelitis
- (2010) J. M. Fletcher et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Diseases associated with thyroid autoimmunity: explanations for the expanding spectrum
- (2010) A. P. Weetman CLINICAL ENDOCRINOLOGY
- A Novel Strategy To Reduce the Immunogenicity of Biological Therapies
- (2010) J. Somerfield et al. JOURNAL OF IMMUNOLOGY
- Immune reconstitution syndrome and the thyroid
- (2009) Anthony Weetman BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes
- (2008) Alice R. Lorenzi et al. ARTHRITIS AND RHEUMATISM
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now